Short-course isoniazid and pyrazinamide compared with 6-month isoniazid for tuberculosis prevention in HIV-infected adults: The randomized clinical trial

Z. M. Zagdyn, S. I. Dyrul, S. Shenoi, G. N. Isaeva, O. V. Gavrilova, E. N. Lebedeva, E. V. Verbitskaya, M. V. Beltyukov, A. Yu Kovelenov, E. G. Sokolovich

Research outputpeer-review

Abstract

The aim of the randomized controlled clinical trial was to compare the efficacy of a 3-month regimen of isoniazid and pyrazinamide with that of a 6-month isoniazid in people living with HIV. Results: From the total 624 enrolled patients treatment was completed by 243 patients in short-course group and by 237 ones in IPT group (p=0,9). Adverse events were established in 6,1% of subjects in combined arm and in 6,7% in isoniazid group (p=0,8). After a follow-up 946,2 person-years, 8 person in isoniazid group and 9 person in compared group developed active TB with TB incidence per 100 person-years 1,9 and 1,8 respectively (p > 0,05). The Caplan-Meyer TB survival probability for the entire group of participants over the follow up period was 0,1306 without statistical differences. Three subjects were died in isoniazid group and one person - in combined group. Conclusion. Our data may suggest that for preventing tuberculosis in HIV-infected patients, a daily 3-month regimen of isoniazid and pyrazinamide is similar in safety and efficacy to a daily 6-month regimen of isoniazid. This shorter regimen offers practical advantages to patients and tuberculosis control programs, improving patients' adherence to TB prevention treatment.

Original languageEnglish
Pages (from-to)54-64
Number of pages11
JournalHIV Infection and Immunosuppressive Disorders
Volume9
Issue number3
DOIs
Publication statusPublished - 1 Jan 2017
Externally publishedYes

Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Short-course isoniazid and pyrazinamide compared with 6-month isoniazid for tuberculosis prevention in HIV-infected adults: The randomized clinical trial'. Together they form a unique fingerprint.

Cite this